Patents by Inventor Hendrik Van Urk
Hendrik Van Urk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9555344Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: GrantFiled: July 14, 2014Date of Patent: January 31, 2017Assignee: Albumedix A/SInventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, David James Ballance, Darrell Sleep
-
Patent number: 9029102Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: GrantFiled: July 1, 2011Date of Patent: May 12, 2015Assignee: Novozymes Biopharma DK A/SInventors: Hendrik Van Urk, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Jean-Luc Bernard Veron
-
Publication number: 20150056654Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: ApplicationFiled: July 14, 2014Publication date: February 26, 2015Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-luc Bernard Veron
-
Patent number: 8349589Abstract: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins can be produced with enhanced stability.Type: GrantFiled: February 21, 2008Date of Patent: January 8, 2013Assignee: Fujifilm Manufacturing Europe B.V.Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Patent number: 8349588Abstract: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: GrantFiled: February 21, 2008Date of Patent: January 8, 2013Assignee: Fujifilm Manufacturing Europe B.V.Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Patent number: 8198047Abstract: The invention concerns recombinant gelatins with unevenly distributed RGD motifs that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: GrantFiled: February 21, 2008Date of Patent: June 12, 2012Assignee: Fujifilm Manufacturing Europe B.V.Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Patent number: 8173776Abstract: The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: GrantFiled: December 2, 2011Date of Patent: May 8, 2012Assignee: Fujifilm Manufacturing Europe B.V.Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20120107372Abstract: The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBEmonomersequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: ApplicationFiled: December 2, 2011Publication date: May 3, 2012Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Patent number: 8158756Abstract: The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: GrantFiled: February 21, 2008Date of Patent: April 17, 2012Assignee: Fujifilm Manufacturing Europe B.V.Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20110301329Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: ApplicationFiled: July 1, 2011Publication date: December 8, 2011Applicant: Novozymes Biopharma DK A/SInventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
-
Patent number: 7993877Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.Type: GrantFiled: September 9, 2008Date of Patent: August 9, 2011Assignee: Novozymes Biopharma DK A/SInventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
-
Publication number: 20100256075Abstract: The present invention relates to high molecular weight gelatin-like proteins and methods for producing high yields thereof. Also, compositions comprising one or more of such proteins are provided.Type: ApplicationFiled: September 9, 2008Publication date: October 7, 2010Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20100119574Abstract: The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: ApplicationFiled: February 21, 2008Publication date: May 13, 2010Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20100105618Abstract: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins can be produced with enhanced stability.Type: ApplicationFiled: February 21, 2008Publication date: April 29, 2010Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20100075902Abstract: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: ApplicationFiled: February 21, 2008Publication date: March 25, 2010Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Publication number: 20100062531Abstract: The invention concerns recombinant gelatins with unevenly distributed RGD motifs that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.Type: ApplicationFiled: February 21, 2008Publication date: March 11, 2010Inventors: Arjo Lysander De Boer, Hendrik Van Urk, Jan Bastiaan Bouwstra, Peter Franciscus Theresius Maria Van Asten
-
Patent number: 7601515Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.Type: GrantFiled: April 23, 2007Date of Patent: October 13, 2009Assignee: Novozymes Biopharma UK LimitedInventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
-
Publication number: 20090171070Abstract: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.Type: ApplicationFiled: September 9, 2008Publication date: July 2, 2009Applicant: NOVOZYMES BIOPHARMA UK LIMITEDInventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
-
Publication number: 20080009042Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, for example ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin and affinity chromatography binding contaminants. Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.Type: ApplicationFiled: April 23, 2007Publication date: January 10, 2008Applicant: NOVOZYMES DELTA LIMITEDInventors: Andrew Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Woodrow, Richard Johnson, Patricia Wood, Stephen Burton, Alan Quirk
-
Patent number: 7223561Abstract: A process is provided for the preparation of albumin which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises passing albumin (preferably expressed and secreted by transformed yeast) through positive mode cation exchange and then positive mode anion exchange chromatography. Other steps may also be employed, ultrafiltration, gel permeation chromatography, affinity chromatography binding the albumin by using blue dyes) and affinity chromatography binding contaminants by using an aminophenylboronic acid resin. Elution of albumin, with a compound having affinity for albumin, from a material having no specific affinity for albumin is also disclosed, as is removal of ammonium ions with a counter-ion.Type: GrantFiled: June 22, 2004Date of Patent: May 29, 2007Assignee: Novozymes Delta, LimitedInventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk